Table 1.
Patient characteristics at diagnosis after propensity score matching
| All patients (N = 276) | Six cycles of standard regimens (n = 138) | Eight cycles of standard regimens (n = 138) | P value | SMD | Survivor (n = 203) | Non-survivor (n = 73) | P value | |
|---|---|---|---|---|---|---|---|---|
| Age, years, median (range) | 72 (27-90) | 72 (33-90) | 72 (27-87) | 0.345 | 72 (27-90) | 72 (33-89) | 0.482 | |
| ≥70, n (%) | 155 (56.2) | 75 (54.3) | 80 (58.0) | 0.628 | 0.073 | 114 (56.2) | 41 (56.2) | 0.999 |
| Male, n (%) | 144 (52.2) | 71 (51.4) | 73 (52.9) | 0.904 | 0.029 | 101 (49.8) | 43 (58.9) | 0.219 |
| ECOG PS ≥2, n (%) | 59 (21.4) | 33 (23.9) | 26 (18.8) | 0.378 | 32 (15.8) | 27 (37.0) | <0.001 | |
| Extranodal sites ≥2, n (%) | 96 (34.8) | 45 (32.6) | 51 (37.0) | 0.528 | 69 (34.0) | 27 (37.0) | 0.669 | |
| Ann Arbor stage III/IV, n (%) | 187 (67.8) | 90 (65.2) | 97 (70.3) | 0.440 | 130 (64.0) | 57 (78.1) | 0.029 | |
| Elevated LDH (>ULN), n (%) | 181 (65.6) | 86 (62.3) | 95 (68.8) | 0.311 | 123 (60.6) | 58 (79.5) | 0.004 | |
| Serum albumin (g/dl), median (range) | 3.6 (1.1-5.1) | 3.5 (1.4-5.1) | 3.6 (1.1-4.9) | 0.648 | 3.6 (1.1-5.1) | 3.4 (1.6-4.9) | 0.006 | |
| IPI, n (%) | ||||||||
| Low/low intermediate (0-2) | 117 (42.4) | 61 (44.2) | 56 (40.6) | 0.626 | 0.073 | 96 (47.3) | 21 (28.8) | 0.006 |
| High intermediate/high (≥3) | 159 (57.6) | 77 (55.8) | 82 (59.4) | 107 (52.7) | 52 (71.2) | |||
| NCCN-IPI, n (%) | ||||||||
| Low/low intermediate (0-3) | 96 (34.8) | 49 (35.5) | 47 (34.1) | 0.899 | 0.030 | 81 (39.9) | 15 (20.5) | 0.003 |
| High intermediate/high (≥4) | 180 (65.2) | 89 (64.5) | 91 (65.1) | 122 (60.1) | 58 (79.5) | |||
| Bulky mass, n (%) | 52 (18.8) | 24 (17.4) | 28 (20.3) | 0.645 | 0.074 | 34 (16.7) | 18 (24.7) | 0.163 |
| B symptoms, n (%) | 91 (33.0) | 43 (31.2) | 48 (34.8) | 0.609 | 61 (30.0) | 30 (41.1) | 0.110 | |
| Uric acid (mg/dl), median (range) | 5.3 (0.2-23.0) | 5.4 (0.2-13.7) | 5.0 (1.1-23.0) | 0.327 | 5.1 (0.2-23.0) | 6.0 (0.7-13.7) | 0.052 | |
| ≥7.5 mg/dl | 37 (13.4) | 18 (13.0) | 19 (13.8) | 0.999 | 0.021 | 23 (11.3) | 14 (19.2) | 0.109 |
| sIL-2R, median (range) | 1441 (168-38 400) | 1343 (168-38 400) | 1478 (260-25 400) | 0.943 | 1200 (168-25 400) | 3021 (316-38 400) | <0.001 | |
| ≥Median | 145 (52.5) | 70 (50.7) | 75 (54.3) | 0.630 | 0.073 | 95 (46.8) | 50 (68.5) | 0.002 |
| CCI, n (%) | ||||||||
| Low/medium (0-2) | 234 (84.8) | 116 (84.1) | 118 (85.5) | 0.867 | 0.040 | 173 (85.2) | 61 (83.6) | 0.708 |
| High/very high (≥3) | 42 (15.2) | 22 (15.9) | 20 (14.5) | 30 (14.8) | 12 (16.4) | |||
| GNRI, n (%) | ||||||||
| No-risk group (>98) | 104 (37.7) | 52 (37.7) | 52 (37.7) | 0.999 | <0.001 | 66 (32.5) | 38 (52.1) | 0.005 |
| Risk group (≤98) | 172 (62.3) | 86 (62.3) | 86 (62.3) | 137 (67.5) | 35 (47.9) | |||
| Total ARDI | 98.8 (119.2-142.6) | 91.6 (19.2-106.4) | 123.1 (61.2-142.6) | <0.001 | 99.3 (35.4-142.6) | 92.4 (19.2-138.0) | 0.067 | |
| ASCT | 17 (6.2) | 14 (10.1) | 3 (2.2) | 0.010 | 8 (3.9) | 9 (12.3) | 0.020 | |
| Up-front ASCT | 12 (4.3) | 12 (8.7) | 0 (0.0) | <0.001 | 6 (3.0) | 6 (8.2) | 0.088 | |
| ASCT as salvage therapy | 5 (1.8) | 2 (1.4) | 3 (2.2) | 0.999 | 2 (1.0) | 3 (4.1) | 0.117 |
ASCT, autologous stem cell transplantation; CCI, Charlson Comorbidity Index; ECOG PS, Eastern Cooperative Oncology Group performance status; GNRI, Geriatric Nutritional Risk Index; IPI, International Prognostic Index; LDH, lactate dehydrogenase; NCCN, National Comprehensive Cancer Network; sIL-2R, soluble interleukin-2 receptor; SMD, standardized mean difference; ULN, upper limit of normal.